Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Years of experience
Clients
Studied molecules
Latest news

Retour sur les AFSSI Connections 2021
Retour sur les tables rondes du 28 septembre dernier... ➤ avec le programme complet de cette...
more news>
useful ressources
job offers/application
contact us